- $5.37m
- -$6.50m
- AU$0.02m
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 0.24 | ||
Price to Tang. Book | 0.74 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 363.65 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -84.79% | ||
Return on Equity | -70.72% | ||
Operating Margin | -149490.84% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | AU$m | 0.91 | 0.05 | n/a | 0.26 | 0.02 | 1.44 | 2.2 | -60.5% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Bionomics Ltd is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on development of novel drug candidates focused on the treatment of serious central nervous system disorders. It is developing novel allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need. It is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder (SAD) and chronic treatment of post-traumatic stress disorder (PTSD). Its α7 Receptor Positive Allosteric Modulators (PAMs) pipeline is targeting cognitive dysfunction associated with Alzheimer’s disease and other central nervous system conditions. The Company’s CNS pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels.
Directors
- Last Annual
- June 30th, 2023
- Last Interim
- June 30th, 2023
- Incorporated
- September 27th, 1996
- Public Since
- December 21st, 1999
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 1,468,735,424
- Address
- 200 Greenhill Road, THEBARTON, 5063
- Web
- https://www.bionomics.com.au/
- Phone
- +61 881507400
- Auditors
- Ernst & Young
Upcoming Events for BNOX
Similar to BNOX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
Actuate Therapeutics
NASDAQ Global Market
FAQ
As of Today at 20:04 UTC, shares in Bionomics are trading at $0.66. This share price information is delayed by 15 minutes.
Shares in Bionomics last closed at $0.66 and the price had moved by -50.84% over the past 365 days. In terms of relative price strength the Bionomics share price has underperformed the S&P500 Index by -61.12% over the past year.
The overall consensus recommendation for Bionomics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreBionomics does not currently pay a dividend.
Bionomics does not currently pay a dividend.
Bionomics does not currently pay a dividend.
To buy shares in Bionomics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.66, shares in Bionomics had a market capitalisation of $5.37m.
Here are the trading details for Bionomics:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: BNOX
Based on an overall assessment of its quality, value and momentum Bionomics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bionomics is $6.00. That is 810.89% above the last closing price of $0.66.
Analysts covering Bionomics currently have a consensus Earnings Per Share (EPS) forecast of -AU$3.12 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bionomics. Over the past six months, its share price has underperformed the S&P500 Index by -41.47%.
As of the last closing price of $0.66, shares in Bionomics were trading -30.49% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bionomics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.66.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Bionomics' directors